CHV

Centre Hospitalier de Versailles

corporate_fareorganization

Web page: http://www.ch-versailles.fr/

Country: France

ROR: https://ror.org/053evvt91

ISNI: 0000000121777052

CHV

- Funding / Projects
  (8)

8 Projects, page 1 of 2

ACTIW / CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE: AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN.
assignment_turned_inProjectPartners:CHV
CHV
Funder: Institut National du Cancer Project Code: INCa-DGOS-8599
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Phase III multicenter trial comparing imatinib 400mg versus imatinib 600mg versus imatinib 400 mg plus cytarabine versus imatinib 400 mg combine with pegylated Interferona2a for the treatment of patients with chronic myeloid leukaemia in chronic phase-SPIRIT Ancillary study A pharmacogenetic study of response and tolerance to imatinib alone or in combination in patients treated for de novo chronic phase CML.
assignment_turned_inProjectPartners:Centre Hospitalier Universitaire d'Angers, Hôpital Claude Huriez, Hôpital Morvan, CHU Nantes - Hôtel Dieu, Hôpital Édouard Herriot +14 partners
Centre Hospitalier Universitaire d'Angers,
Hôpital Claude Huriez,
Hôpital Morvan,
CHU Nantes - Hôtel Dieu,
Hôpital Édouard Herriot,
Hôpital Purpan,
Groupe Hospitalier Henri Mondor - Albert Chenevier,
Hôtel-Dieu,
Hôpital Albert Calmette,
Hôpitaux de Brabois Adultes-Enfants,
CHV,
Hôpital Necker- Enfants malades,
Hôpital Pellegrin,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Nîmes,
Hôpital Hôtel-Dieu,
Hôpital Robert Debré,
Hôpital Saint-Louis,
Hôpital de l'Archet
Funder: Institut National du Cancer Project Code: INCa-DGOS-3706
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
RILUZOX-01. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study of the UNICANCER-AFSOS Supportive Care intergroup.
assignment_turned_inProjectPartners:Institut Gustave Roussy, Hôpital Nord, CHU Dijon-Bourgogne - Centre Hospitalier Universitaire de Dijon, Hôpital Morvan, Hôpital Hôtel-Dieu +5 partners
Institut Gustave Roussy,
Hôpital Nord,
CHU Dijon-Bourgogne - Centre Hospitalier Universitaire de Dijon,
Hôpital Morvan,
Hôpital Hôtel-Dieu,
Centre Eugène Marquis,
CHV,
Centre Georges-François Leclerc,
Université de Franche-Comté,
Institut Curie
Funder: Institut National du Cancer Project Code: INCa-DGOS-11128
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Essai pilote du Brentuximab Vedotin (SNG35) associé à l’AVD dans le traitement du lymphome hodgkinien de stade III-IV lié au VIH – AMC 85 (seconde phase de l’essai correspondant au suivi des patients)
assignment_turned_inProjectUntil 2022Partners:CHV
CHV
Funder: Institut National du Cancer Project Code: INCa-14174
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
The hypothesis of therapeutic targeting of the iNKT/« innate-memory » T cell axis with Dasatinib in chronic myeloid leukemia
assignment_turned_inProject2015 - 2018Partners:Centre Hospitalier Universitaire de Poitiers, INSERM U1082, CHV
Centre Hospitalier Universitaire de Poitiers,
INSERM U1082,
CHV
Funder: Institut National du Cancer Project Code: INCa-8658
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
chevron_right

CHV

CHV

Funder

8 Projects, page 1 of 2

ACTIW / CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE: AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN.

RILUZOX-01. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study of the UNICANCER-AFSOS Supportive Care intergroup.

Essai pilote du Brentuximab Vedotin (SNG35) associé à l’AVD dans le traitement du lymphome hodgkinien de stade III-IV lié au VIH – AMC 85 (seconde phase de l’essai correspondant au suivi des patients)

The hypothesis of therapeutic targeting of the iNKT/« innate-memory » T cell axis with Dasatinib in chronic myeloid leukemia

Loading